| Rhonda F. Farnum |
Ms. Rhonda F. Farnum is a Chief Business Officer & SVP-Medical Affairs at Theravance Biopharma, Inc. Ms. Farnum was previously employed as a Head-Hematology Business Unit by Onyx Pharmaceuticals, Inc. She received her undergraduate degree from the University of Georgia. |
| Richard A. Graham |
Richard A. Graham is currently working as the Senior Vice President-Research & Development at Theravance Biopharma, Inc. Previously, he held the position of Head-Translational Medicine at Onyx Pharmaceuticals, Inc. and Vice President-Clinical Development at Clinical Pharmacology Center, Inc. Dr. Graham has an undergraduate and graduate degree from Iowa State University. He also holds a doctorate degree from UNC School of Law and the University of North Carolina at Chapel Hill. |
| Stacy Pryce |
Stacy Pryce currently works as the Chief Strategy Officer & Senior Vice President at Theravance Biopharma, Inc. |
| Aziz Sawaf |
Mr. Aziz Sawaf is a Chief Financial Officer & Senior Vice President at Theravance Biopharma, Inc. He is on the Board of Directors at California Life Sciences Association. He received his undergraduate degree from the University of Arizona, a graduate degree from The Johns Hopkins University and an MBA from USC Marshall School of Business. |
| Stuart Knight |
Stuart Knight is currently the Chief Information Officer, Vice President-IT&I at Theravance Biopharma, Inc. He previously worked as the Head-Global Markets IT & Infrastructure at Galderma Pharma SA from 2013 to 2014 and as the Vice President-Information Technology at Ipsen Biopharmaceuticals, Inc. from 2008 to 2013. Mr. Knight completed his undergraduate degree at London South Bank University. |
| Rick E. Winningham |
Rick E. Winningham is the founder of Praxis Bioresearch LLC, which was founded in 2014. He is currently the Chairman & Chief Executive Officer of Theravance Biopharma, Inc. since 2013 and the Chief Executive Officer of Theravance Biopharma US, Inc. He is also a Director at Biotechnology Innovation Organization since 2014, Lead Independent Director at Jazz Pharmaceuticals Plc since 2010, and a Director at California Biomedical Innovation Alliance since 2015. Mr. Winningham has held former positions as Chairman at Innoviva, Inc. from 2001 to 2014, Chairman at California Healthcare Institute from 2011 to 2015, Chairman at Retrotope, Inc. in 2021, Chairman at California Life Sciences Association in 2015, and President-Global Marketing at Bristol Myers Squibb Co. from 1997 to 2001. He has also served as an Independent Director at OncoMed Pharmaceuticals, Inc. from 2015 to 2019. Mr. Winningham holds an MBA from Texas Christian University and an undergraduate degree from Southern Illinois University. |
| Laurie Smaldone Alsup |
Dr. Laurie S. Alsup, MD, is an Independent Director at Arvinas, Inc., an Independent Director at Theravance Biopharma, Inc., a Senior Vice President-Regulatory Science at NDA Group AB and an Independent Director at BlackBerry Ltd. She is on the Board of Directors at Arvinas, Inc., Theravance Biopharma, Inc., BlackBerry Ltd. and Arvinas Operations, Inc. Dr. Alsup was previously employed as a Lead Independent Director by Pardes Biosciences, Inc., an Independent Director by Kinnate Biopharma, Inc., an Independent Director by KaloBios Pharmaceuticals, Inc., a President & Chief Scientific Officer by PharmApprove LLC, a President & Chief Executive Officer by Phytomedics, Inc., and a Senior Vice President-Global Regulatory Science by Bristol Myers Squibb Co. She also served on the board at Kalobios Pharmaceuticals, Inc. She received her undergraduate degree from Fordham University and a doctorate degree from Yale School of Medicine. |
| Burton Gordon Malkiel |
Dr. Burton G. Malkiel is an Independent Director at Theravance Biopharma, Inc., a Chief Investment Officer at Wealthfront Advisers LLC, a Chief Investment Officer at Wealthfront Corp. and a Professor-Emeritus at Princeton University. He is on the Board of Directors at Theravance Biopharma, Inc., American Philosophical Society, Genmab, Inc., The Maldeb Foundation, Inc. and Corvina Foundation, Inc. Dr. Malkiel was previously employed as a Co-Founder & Chairman by Baochuan Capital Management LLC, an Independent Director by Theravance, Inc., a Chief Investment Officer by AlphaShares LLC, an Independent Director by Genmab A/S, a Dean by Yale School of Management, a President by American Finance Association, a Member by Council of Economic Advisers, a President by International Atlantic Economic Society, an Investment Banker by Smith Barney & Co., Inc., and an Officer by United States Army Finance Corps. He also served on the board at BKF Capital Group, Inc. and The Vanguard Group, Inc. He received his undergraduate degree from Harvard University, an MBA from Harvard Business School and a doctorate degree from Princeton University. |
| Eran Broshy |
Mr. Eran Broshy is a Chairman at Thirty Madison, Inc., an Independent Director at Certara, Inc., a Chairman at ERT Operating Co., an Independent Director at Theravance Biopharma, Inc., a Chairman at American Friends of The Open University of Israel, a Member at Massachusetts Institute of Technology, a Member at MIT Corp. (United States), a Member-Governors Board at The American Jewish Committee and a President, Director & Manager at Dermarite Holdings LLC. He is on the Board of Directors at Certara, Inc., Theravance Biopharma, Inc., Simon Wiesenthal Center, Inc. and Dermarite Holdings LLC. Mr. Broshy was previously employed as an Operating Partner by Court Square Capital Partners, an Operating Partner by Linden Manager LLC, an Independent Director by Magellan Health, Inc., a Senior Advisor by Providence Equity Partners LLC, a Chairman by inVentiv Health, Inc., a Chairman by Ventiv Health, Inc., a President & Chief Executive Officer by Coelacanth Corp., a Managing Partner by The Boston Consulting Group, Inc., and a Chairman by Virtual Radiologic Corp. He also served on the board at Nordic Capital Corp., Tailwind Capital LLC, Union Street Acquisition Corp., Neurogen Corp., Correlagen Diagnostics, Inc., HeartFlow, Inc., Israel Venture Network and Visiant Holdings, Inc. He received his undergraduate degree from Massachusetts Institute of Technology, a graduate degree from Stanford University and an MBA from Harvard Business School. |
| Deepa R. Pakianathan |
Dr. Deepa R. Pakianathan is an Independent Director at Palleon Pharmaceuticals, Inc., an Independent Director at Theravance Biopharma, Inc., a Chief Executive Officer at Redd Pharmaceuticals, Inc., an Independent Non-Executive Director at Mereo BioPharma Group Plc, an Independent Director at Karyopharm Therapeutics, Inc., a Lead Independent Director at Calithera Biosciences, Inc., a Managing Partner at Delphi Ventures, Inc., an Executive Vice Chairman & Treasurer at San Francisco Conservatory of Music, a Managing Member at Delphi Management Partners VII LLC, a Managing Member at Delphi Management Partners VIII LLC and a Managing Member at Delphi Ventures III LP. She is on the Board of Directors at Palleon Pharmaceuticals, Inc., Theravance Biopharma, Inc., Mereo BioPharma Group Plc, Karyopharm Therapeutics, Inc., Calithera Biosciences, Inc. and San Francisco Conservatory of Music. Dr. Pakianathan was previously employed as an Independent Director by FS Development Corp. II, an Independent Director by FS Development Corp., an Independent Director by Alder Biopharmaceuticals, Inc., an Independent Director by OncoMed Pharmaceuticals, Inc., an Independent Director by Alexza Pharmaceuticals, Inc., a Vice President by J.P. Morgan & Co. Ltd., a Senior Biotechnology Banker by J.P. Morgan Partners LLC, a Research Analyst by Genesis Merchant Group Securities LLC, and a Postdoctoral Scientist by Genentech, Inc. She also served on the board at PTC Therapeutics, Inc., NeurAxon, Inc., Relypsa, Inc., Phenomix Corp., Adiana, Inc., Antipodean Pharmaceuticals, Inc., Ilypsa, Inc., National Venture Capital Association and Proteolix, Inc. She received her undergraduate degree from the University of Mumbai, a graduate degree from the University of Mumbai, a graduate degree from the Advanced Centre for Treatment Research & Education in Cancer, a graduate degree from Wake Forest University and a doctorate degree from Wake Forest University. |
| Jeremy Todd Grant |
Mr. Jeremy T. Grant, CFA, is an Independent Director at Theravance Biopharma, Inc. and an Associate Portfolio Manager at Elliott Management Corp. He is on the Board of Directors at Theravance Biopharma, Inc. and Acosta, Inc. He received his undergraduate degree from The Wharton School of the University of Pennsylvania. |
| Susannah Gray |
Ms. Susannah Gray is an Independent Director at Theravance Biopharma, Inc., an Independent Director at Morphic Holding, Inc., an Independent Director at Maravai Lifesciences Holdings, Inc. and an Independent Director at 4D Molecular Therapeutics, Inc. She is on the Board of Directors at Theravance Biopharma, Inc., Morphic Holding, Inc., Morphic Therapeutic, Inc., Maravai Lifesciences Holdings, Inc., 4D Molecular Therapeutics, Inc., Biosplice LLC, Biosplice Therapeutics, Inc., Colby College Museum of Art, Maravai Life Sciences, Inc., StreetSquash, Susan G. Komen Foundation, The German Marshall Fund of United States and Wesleyan University. Ms. Gray was previously employed as an Independent Director by Apria, Inc., an Executive Vice President-Finance & Strategy by Royalty Pharma Management LLC, an Executive Vice President-Finance & Strategy by RP Management LLC, an Analyst by CIBC World Markets Corp. (Old), and a Managing Director by Merrill Lynch & Co., Inc. /Old/. She also served on the board at Susan G. Komen for the Cure. She received her undergraduate degree from Wesleyan University and an MBA from Columbia Business School. |
| Jim C. Kelly |
Mr. Jim C. Kelly is an Independent Director at Theravance Biopharma, Inc. and an Investor at Weiss Asset Management LP. He is on the Board of Directors at Theravance Biopharma, Inc. Mr. Kelly was previously employed as an Investment Professional by Farallon Capital Management LLC, an Associate by Madison Dearborn Partners LLC, and a Principal by Lehman Brothers, Inc. He received his undergraduate degree from Duke University. |
| Donal M. O'Connor |
Mr. Donal M. O'Connor is an Independent Director at Theravance Biopharma, Inc., an Independent Director at Perrigo Co. Plc, a Chairman at Huttonread, a Chairman at Galco Steel Ltd. and a Vice President-Strategic Planning at CEMEX UK. He is on the Board of Directors at Theravance Biopharma, Inc. and Perrigo Co. Plc. Mr. O'Connor was previously employed as a Chairman by Malin Corp. Plc, a Senior Independent Non-Executive Director by ReadyMix Plc, a Chairman by Anglo Irish Bank Corp. Plc, a Chairman by Anglo Irish Bank Corp. Ltd., an Independent Non-Executive Director by Elan Corp. Plc, an Administrator by Icarom Plc, a Senior Partner by PricewaterhouseCoopers Ireland LLP, and a Member-Supervisory Board by CEMEX Deutschland AG. He also served on the board at Irish Auditing & Accounting Supervisory Authority. He received his undergraduate degree from the University College Dublin. |
| Dean Jonathan Mitchell |
Mr. Dean J. Mitchell is an Independent Chairman at Praxis Precision Medicines, Inc., a Lead Independent Director at Theravance Biopharma, Inc. and an Independent Director at Precigen, Inc. He is on the Board of Directors at Theravance Biopharma, Inc. and Precigen, Inc. Mr. Mitchell was previously employed as a Chairman by Kinnate Biopharma, Inc., a Chairman by PaxVax, Inc., a Chairman by Paxvax Corp., a Chairman by Covis Pharma Holdings BV, an Executive Chairman by Covis Pharma Holdings SARL, an Independent Director by ImmunoGen, Inc., a President, Chief Executive Officer & Director by Lux Biosciences, Inc., a President, Chief Executive Officer & Director by Alpharma LLC, a President & Chief Executive Officer by Alpharma LLC, a President by MGI GP, Inc., a Non-Executive Director by MGI PHARMA, Inc., a President, Chief Executive Officer & Director by Guilford Pharmaceuticals, Inc., a President-International Pharmaceuticals by Bristol Myers Squibb Co., a Senior VP-Clinical Development & Product Strategy by GlaxoSmithKline Plc, and a Chairman by National Pharmaceutical Council. He also served on the board at Talecris Biotherapeutics Holdings Corp. and ISTA Pharmaceuticals, Inc. He received his undergraduate degree from Coventry University and an MBA from Bayes Business School. |
